Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Agnico Eagle Mines

American Electric Power Company

Target

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The Dow Jones industrial average is down a stunning 3,200 points this week, and we have given back almost five months worth of gains in six trading sessions.

The Fed May Have to Lower Rates Soon: Buy These Safe Dividend Stocks Now

Bristol-Myers' Liso-Cel Given Priority Review, Ability To Change Scope Of Treatment

AbbVie

Bausch Health Companies Inc

These three pharma stocks offer safe harbor in a volatile market.

3 Value Stocks to Buy if the Stock Market Implodes

bluebird bio

Intuitive Surgical

It's not just their cancer treatments that make these stocks attractive.

3 Cancer Treatment Stocks  to Buy Right Now

Success for the Celgene merger rests heavily on new drug approvals the U.S. Food and Drug Administration could deliver in March.

A Big Month Ahead for the FDA and Bristol-Myers Squibb

Bristol-Myers Squibb Makes Case For Success Of Opdivo With Latest Long-Term Kidney Cancer Data

GlaxoSmithKline

Mylan

Novartis

Pfizer

Teva Pharmaceutical

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

Carnival

Foot Locker

MPLX

Bank OZK

Unum

ViacomCBS

7 High-Yield Stocks I'm Buying For My Retirement Portfolio In This Red-Hot Market

Which of these top pharma stocks is the better buy right now?

Better Buy: GlaxoSmithKline vs.  Bristol-Myers Squibb

Biogen

Does the potential of a home run for Biogen with its Alzheimer's disease candidate outweigh the strong lineup and pipeline that Bristol-Myers Squibb offers?

Better Buy: Biogen vs.  Bristol-Myers Squibb

Gilead Sciences

These businesses have the winning trifecta: a stable dividend, ongoing earnings growth, and attractive valuation.

3 High-Yielding U.S. Pharmaceutical Companies to Consider

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

A decision on the cancer therapy is expected by Aug. 17.

FDA Gives Bristol-Myers Squibb's CAR-T Liso-Cel a Priority Review

Abbott Labs

AstraZeneca

Eli Lilly

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

The acquisition of Celgene is working wonders so far.

Bristol-Myers Squibb Stock Is Too Cheap to Ignore

Broadcom

Polaris

I'm Buying 3 Of These 5 Amazing Dividend Stocks For My Retirement Portfolio

Bristol-Myers Squibb's Composite Rating was lifted to 98 putting it near the top of all companies for  fundamental and technical stock-picking criteria.
The post Bristol-Myers Squibb Rides Earnings To Composite Rating Hike appeared first on Investor's Business Daily.

Bristol-Myers Squibb Rides Earnings To Composite Rating Hike

Pharmaceutical company Bristol-Myers advanced in 2019 despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

Bristol-Myers Posts Bullish Growth — But Is It Time To Add BMY Stock?

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

Celgene

Before the market opened on Feb. 6, Bristol-Myers Squibb (NYSE:BMY) reported earnings for the fourth quarter and full-year 2019.

Bristol-Myers Squibb Smashes Earnings Predictions Following Celgene Acquisition

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q4 2019 Results - Earnings Call Transcript

The pharmaceutical giant's guidance also looks good.

Bristol-Myers Squibb's Earnings Get a Boost From Celgene Acquisition

How Bristol-Myers Squibb Trounced Wall Street's Q4 Estimates

Pharmaceutical company Bristol-Myers is remaking itself in the wake of its Celgene merger, says CEO Giovanni Caforio. BMY stock has run up 54% after hitting a low point six months ago.

CEO Q&A: Here's What You Need To Know About The New Bristol-Myers

Bristol-Myers (BMY) delivered earnings and revenue surprises of 38.64% and 29.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Bristol-Myers Stock (BMY)